Maximizing the success of biosimilar implementation

Rieke Alten¹, Max Weinbrecht-Mischkewitz^{2

3}

Affiliations

¹ Department of Internal Medicine, Rheumatology, Clinical Immunology and Osteology, Schlosspark-Klinik, University Medicine, Berlin, Germany. rieke.alten@schlosspark-klinik.de.
² Department of Internal Medicine, Rheumatology, Clinical Immunology and Osteology, Schlosspark-Klinik, University Medicine, Berlin, Germany.
³ Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.

Rieke Alten et al. Nat Rev Rheumatol. 2023 Dec.

. 2023 Dec;19(12):757-758.

doi: 10.1038/s41584-023-01048-7.

Rieke Alten¹, Max Weinbrecht-Mischkewitz^{2

3}

¹ Department of Internal Medicine, Rheumatology, Clinical Immunology and Osteology, Schlosspark-Klinik, University Medicine, Berlin, Germany. rieke.alten@schlosspark-klinik.de.
² Department of Internal Medicine, Rheumatology, Clinical Immunology and Osteology, Schlosspark-Klinik, University Medicine, Berlin, Germany.
³ Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.

No abstract available

References

1. AG Pro Biosimilars. [Biosimilars unter der Lupe]. https://probiosimilars.de/publikationen/marktdaten/ (2023).
1. Kay, J. et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann. Rheum. Dis. 77, 165–174 (2018). - DOI - PubMed
1. European Medicines Agency. Biosimilars in the EU. https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-informatio... (2019).
1. Cohen, H. P. & McCabe, D. The importance of countering biosimilar disparagement and misinformation. BioDrugs 34, 407–414 (2020). - DOI - PubMed - PMC
1. Alten, R. et al. Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis. Int. J. Rheum. Dis. 23, 1514–1525 (2020). - DOI - PubMed - PMC